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Clinical oncology is poised to benefit from continued advances in pharmacogenetics,molecular diagnostics, and targeted therapeutics. The importance of personalized medi-
cine in oncology is reflected in the theme of the 2009 American Society of Clinical Oncology
annual meeting: “Personalizing Cancer Care.” In concert with this era of discovery, important
advances in non-small cell lung cancer (NSCLC) research have emerged. Molecular signatures
of NSCLC have been used to prognosticate survival,1,2 and rational approaches to targeted
therapy have been integrated with chemotherapy in clinical trials with successful outcomes.3,4
So, it may seem surprising that, despite technological advances in the field, identifying readily
available prognostic factors for survival after NSCLC diagnosis continues to hold value.
Clinicopathologic factors such as age at diagnosis, gender, stage at presentation, histologic cell
type, degree of tumor differentiation, performance status, and smoking status may be
technologically mundane, but they continue to have robust prognostic implications for survival
after NSCLC diagnosis. Importantly, these factors are easily accessible from the medical
record to the busy medical oncologist in clinical practice. Numerous studies have reported on
the importance of readily available prognostic factors for survival in NSCLC, sometimes with
conflicting results. This places the focus of interpreting prognostic NSCLC studies on data
quality. In this issue of the Journal of Thoracic Oncology, Chansky et al. on behalf of the
International Association for the Study of Lung Cancer (IASLC) International Staging
Committee (ISC) and Participating Institutions performed a retrospective analysis of 9137
surgically managed stage I-III NSCLC cases from the original IASLC database.5
As first published in the JTO in 2007, the IASLC database represents a landmark
achievement in establishing accurate reassessments of tumor, node, metastasis (TNM) de-
scriptors and stage groupings for NSCLC and small cell lung cancer.6–11 The purpose of these
studies was to inform the recently released 2009 revisions to the Union Internationale Contre
le Cancer -7 staging system for lung cancer, which were clearly in need of revision (as best
demonstrated by results of the IASLC ISC analyses). This project was the largest of its kind
to date, involving analysis of 67,725 NSCLC cases collected worldwide during 1990–2000,
along with an external validation study using data from the United States Surveillance,
Epidemiology, and End Results SEER database. The original findings and recommendations
from the IASLC ISC have refined the new Union Internationale Contre le Cancer staging
system to more accurately define risk groups by stage. In doing so, results from the IASLC ISC
will now inform therapeutic management decisions with practice-changing consequences.
Findings from the IASLC database have been validated by IASLC as noted, externally
validated by our group,12–14 and additional studies will likely emerge to test the relevance of
these TNM descriptors and stage groupings in various NSCLC tumor databases. Already,
IASLC has embarked on an ongoing project to create a prospectively derived NSCLC
database that will provide future refinements to the lung cancer staging system and validations
of many more clinical, laboratory, and molecular prognostic markers.
Previously, the Prognostic Factors Subcommittee of the ISC has reported on the relevant
prognostic factors for survival among 12,428 NSCLC cases.15 The accompanying article by
Chansky et al.5 reveals a detailed analysis of a less heterogenous group of NSCLC cases: stage
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I–III cases that received surgical resection. In this article, the
authors demonstrate that the previously identified clinicopatho-
logic characteristics: age70 years, male gender, and advanced
stage at presentation were associated with poor survival among
resected NSCLC cases. Interestingly, histology (other than bron-
chioloalveolar carcinoma, BAC) was less important in their
analysis. Squamous cell carcinoma histology was found to be an
independent favorable prognostic factor for survival compared
with adenocarcinoma, and a statistically significant interaction
was observed between histology and gender on survival of
NSCLC cases. Thus, the survival differences between squamous
cell carcinoma and adenocarcinoma were observed only among
males, and there was no difference by histologic subtype among
females.With a new histology-based treatment paradigm emerg-
ing in NSCLC,16 such information may be useful for treatment,
but also prognosis, and as potential stratification factors for
clinical trial development. Using recursive partitioning and
amalgamation analysis, the authors demonstrate that pathologic
TNM stage is the most important prognostic factor for overall
survival in NSCLC, and that female gender was a favorable
prognostic factor for those less than 70 years of age. Subset
analyses were performed where limited data were available for
performance status and smoking status, which generally concur
with previously reported findings.
Along with performance status and smoking status,
other readily available prognostic factors are important in
NSCLC research. Degree of tumor differentiation, for exam-
ple, has been consistently and strongly associated with over-
all survival in NSCLC.17 In a large population-based analysis
of stage IA NSCLC cases that underwent lobectomy, degree
of tumor differentiation was prognostic but not histology
(with the exception of bronchioloalveolar carcinoma) after
factoring in age and gender among other clinical factors.17
Thus, it is possible that the results by Chansky et al.5
regarding survival differences by histology (with the excep-
tion of bronchioloalveolar carcinoma) and gender could be
confounded by tumor grade of differentiation. Another po-
tentially important and readily available prognostic factor for
NSCLC survival is the extent of surgical resection, which was
not incorporated into the multivariate models of the present
analysis. We have shown that the number of lymph nodes
removed in stage IA patients who underwent lobectomy was an
independent prognostic factor for survival in NSCLC.17
Because of the high quality of the data source, large
sample size, and the robust statistical analytic approach,
Chansky et al. have provided compelling evidence on the
prognostic importance of age, gender, stage, cell type, and (to
a lesser extent) performance status, and smoking status.
Future meta-analyses of recently published and ongoing ad-
juvant NSCLC treatment trials will provide additional infor-
mation on how modern adjuvant treatment affects the prog-
nostic significance of these factors, since only 8.5% of the
patients in the study by Chanksy et al. received subsequent
chemotherapy. Future studies of prognostic markers in
NSCLC should attempt to validate as many of the prognostic
factors as possible including tumor characteristics, patient
characteristics, laboratory parameters, and indicators of tu-
mor biology, as noted previously by IASLC.15
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